Vidal steps up scrutiny of Fintiv rule-based decisions

Mylan and Edwards Lifesciences argue that the controversial rule safeguards poor-quality patents | US v Arthrex conferred increased authority to Vidal over PTAB decisions.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Vidal issues non-binding guidance on Fintiv denials

23 June 2022 The director of the US Patent and Trademark Office, Kathi Vidal, has unveiled long-anticipated guidance for the procedures governing the discretionary denials that can be handed down by the US Patent Trial and Appeal Board (PTAB) when declining to review a patent’s validity.

Americas

USPTO urges Vidal review of Arthrex petition

19 May 2022 The US Patent and Trademark Office has argued against a bid by medical device maker Arthrex, which wants recognition that an ex-interim acting director lacked the power to refuse to review its petition.

More features

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

UK gets new IP minister following cabinet reshuffle

Barnes & Thornburg reveals five new IP leaders

Vidal steps up scrutiny of Fintiv rule-based decisions

More on this story

Editor's picks

Editor's picks

More features